Watch CLRB. Know when insiders buy.
One email the day a filing lands. Free.
CLRB
Cellectar Biosciences, Inc.
2.37
−0.04 −1.66%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
71
PASS · shorts 71
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $22.4MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$22.3MNET CASH $33.7M52W 2.23 – 6.17SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$7.2M | −$6.9M | — | -0.57 | −$6M | $0 | −$6M | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$5.8M | −$5.7M | — | -1.33 | −$4.8M | $3K | −$4.8M | Aug 13 |
| Q4 2025 · Dec 31derived | — | — | — | −$5.7M | −$5.3M | — | -0.53 | −$4.3M | — | — | Mar 4 |
| Q3 2025 · Sep 30 | — | — | — | −$4.9M | −$4.4M | — | -1.41 | −$4.3M | — | — | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$6M | −$5.4M | — | -3.39 | −$5.1M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$6.4M | −$6.6M | — | -4.30 | −$9.4M | — | — | Aug 13 |
| Q4 2024 · Dec 31derived | — | — | — | −$12.7M | −$2.4M | — | -0.10 | −$10.9M | $61K | −$11M | Mar 4 |
| Q3 2024 · Sep 30 | — | — | — | −$13.3M | −$14.7M | — | -12.13 | −$9.2M | $0 | −$9.2M | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$13.7M | −$919K | — | -5.43 | −$14.1M | $21K | −$14.2M | Nov 13 |
| Q1 2024 · Mar 31 | — | — | — | −$12M | −$26.6M | — | -0.91 | −$13.4M | $22K | −$13.4M | Nov 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$12.5M | −$7.9M | — | -0.41 | −$9.6M | $267K | −$9.9M | Mar 13 |
| Q3 2023 · Sep 30 | — | — | — | −$9.4M | −$17.5M | — | -1.55 | −$8.1M | — | — | Nov 18 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$23M | −$21.8M | — | -8.35 | −$23.1M | $6K | −$23.1M | — | — |
| FY2024 · to Dec 31 | — | — | −$51.8M | −$44.6M | — | -41.89 | −$47.6M | $104K | −$47.7M | — | — |
| FY2023 · to Dec 31 | — | — | −$39M | −$42.8M | — | -3.50 | −$32.4M | $864K | −$33.2M | — | — |
| FY2022 · to Dec 31 | — | — | −$28.8M | −$31.8M | — | -4.51 | −$25.2M | $226K | −$25.4M | — | — |
| FY2021 · to Dec 31 | — | — | −$24.1M | −$24.1M | — | -4.35 | −$22.6M | $141K | −$22.7M | — | — |
| FY2020 · to Dec 31 | — | — | −$15.3M | −$15.1M | — | -1.84 | −$13.9M | $62K | −$14M | — | — |
Every number comes from Cellectar Biosciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.